Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03412877 |
Title | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | National Cancer Institute (NCI) |
Indications | |
Therapies |
Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab |
Age Groups: | senior | adult |
Covered Countries | USA |